Physician profile
Holly E Bennett
NPI 1972826659
$1,322.31
in general payments reported to CMS, 2019-2025
22 companies · $71.57 in 2025
The $71.57 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $914 · 2023: $183 · 2024: $154 · 2025: $71.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $195.21 | 2022-2024 | |
| Abbott Laboratories | $169.42 | 2022-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $150.90 | 2022-2024 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.73 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $85.23 | 2022 | |
| Novo Nordisk INC | $80.03 | 2022 | |
| Exact Sciences Corporation | $71.39 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $61.39 | 2022-2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $50.97 | 2022 | |
| Organon LLC | $48.57 | 2022-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $45.60 | 2022 | |
| Pfizer INC. | $34.55 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.54 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.47 | 2022 | |
| Lundbeck LLC | $28.51 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.30 | 2022 | |
| Mylan Specialty L.P. | $25.90 | 2023 | Yupelri |
| Pharmacosmos Therapeutics INC. | $23.48 | 2024 | Monoferric |
| Currax Pharmaceuticals LLC | $15.71 | 2025 | Contrave |
| Otsuka America Pharmaceutical, INC. | $13.74 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.55 | 2024 | Trulance, Xifaxan |
| Teva Pharmaceuticals USA, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.